{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T16:34:52Z","timestamp":1784219692659,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20fk0210058"],"award-info":[{"award-number":["JP20fk0210058"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s00535-020-01733-4","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T05:52:35Z","timestamp":1601531555000},"page":"67-77","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study"],"prefix":"10.1007","volume":"56","author":[{"given":"Yuki","family":"Tahata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Hikita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Mochida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Ido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Yoshiji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Hiasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Takikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Sakamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Kurosaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yatsuhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Tateishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Kanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goki","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunari","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Asahina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Terai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Takami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Akuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohide","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5036-3457","authenticated-orcid":false,"given":"Tetsuo","family":"Takehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,1]]},"reference":[{"key":"1733_CR1","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/hep.21176","volume":"43","author":"A Sangiovanni","year":"2006","unstructured":"Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology. 2006;43:1303\u201310.","journal-title":"Hepatology"},{"key":"1733_CR2","first-page":"S35","volume":"36","author":"LB Seeff","year":"2002","unstructured":"Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:S35\u201346.","journal-title":"Hepatology"},{"key":"1733_CR3","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jhep.2004.01.005","volume":"40","author":"R Planas","year":"2004","unstructured":"Planas R, Balleste B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol. 2004;40:823\u201330.","journal-title":"J Hepatol"},{"key":"1733_CR4","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1007\/s00535-018-1455-1","volume":"53","author":"K Tsuji","year":"2018","unstructured":"Tsuji K, Kurosaki M, Itakura J, et al. Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group. J Gastroenterol. 2018;53:1142\u201350.","journal-title":"J Gastroenterol"},{"key":"1733_CR5","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/hep4.1206","volume":"2","author":"Y Tahata","year":"2018","unstructured":"Tahata Y, Sakamori R, Urabe A, et al. Liver fibrosis is associated with corrected QT prolongation during ledipasvir\/sofosbuvir treatment for patients with chronic hepatitis C. Hepatol Commun. 2018;2:884\u201392.","journal-title":"Hepatol Commun"},{"key":"1733_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/hepr.13328","volume":"49","author":"E Ogawa","year":"2019","unstructured":"Ogawa E, Furusyo N, Nakamuta M, et al. Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: results from a multicenter, real-world cohort study. Hepatol Res. 2019;49:617\u201326.","journal-title":"Hepatol Res"},{"key":"1733_CR7","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1007\/s00535-018-1473-z","volume":"53","author":"H Toyoda","year":"2018","unstructured":"Toyoda H, Atsukawa M, Takaguchi K, et al. Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan. J Gastroenterol. 2018;53:1276\u201384.","journal-title":"J Gastroenterol"},{"key":"1733_CR8","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1111\/hepr.13362","volume":"49","author":"T Mashiba","year":"2019","unstructured":"Mashiba T, Joko K, Kurosaki M, et al. Real-world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): a nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group. Hepatol Res. 2019;49:1114\u201320.","journal-title":"Hepatol Res"},{"key":"1733_CR9","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1111\/hepr.13410","volume":"49","author":"A Tamori","year":"2019","unstructured":"Tamori A, Inoue K, Kagawa T, et al. Intention-to-treat assessment of glecaprevir + pibrentasvir combination therapy for patients with chronic hepatitis C in the real world. Hepatol Res. 2019;49:1365\u201373.","journal-title":"Hepatol Res"},{"key":"1733_CR10","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","volume":"373","author":"MP Curry","year":"2015","unstructured":"Curry MP, O'Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618\u201328.","journal-title":"N Engl J Med"},{"issue":"67","key":"1733_CR11","first-page":"1477","volume":"2018","author":"Panel A-IHG. Hepatitis C Guidance","year":"2018","unstructured":"Panel A-IHG. Hepatitis C Guidance. Update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2018;2018(67):1477\u201392.","journal-title":"Clin Infect Dis"},{"key":"1733_CR12","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL recommendations on treatment of hepatitis C. J Hepatol. 2018;69:461\u2013511.","journal-title":"J Hepatol"},{"key":"1733_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00535-018-1503-x","volume":"54","author":"T Takehara","year":"2019","unstructured":"Takehara T, Sakamoto N, Nishiguchi S, et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. J Gastroenterol. 2019;54:87\u201395.","journal-title":"J Gastroenterol"},{"key":"1733_CR14","unstructured":"Tanaka A, Drafting Committee for Hepatitis Management Guidelines tJSoH. JSH Guidelines for the Management of Hepatitis C Virus Infection: 2019 Update. Hepatol Res 2020."},{"key":"1733_CR15","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/hepr.13296","volume":"49","author":"Y Seko","year":"2019","unstructured":"Seko Y, Moriguchi M, Hara T, et al. Presence of varices in patients after hepatitis C virus eradication predicts deterioration in the FIB-4 index. Hepatol Res. 2019;49:473\u20138.","journal-title":"Hepatol Res"},{"key":"1733_CR16","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/hepr.13471","volume":"50","author":"S Tsuji","year":"2020","unstructured":"Tsuji S, Uchida Y, Uemura H, et al. Involvement of portosystemic shunts in impaired improvement of liver function after direct-acting antiviral therapies in cirrhotic patients with hepatitis C virus. Hepatol Res. 2020;50:512\u201323.","journal-title":"Hepatol Res"},{"key":"1733_CR17","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","volume":"64","author":"GR Foster","year":"2016","unstructured":"Foster GR, Irving WL, Cheung MC, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;64:1224\u2013311.","journal-title":"J Hepatol"},{"key":"1733_CR18","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jhep.2016.05.010","volume":"65","author":"LS Belli","year":"2016","unstructured":"Belli LS, Berenguer M, Cortesi PA, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol. 2016;65:524\u201331.","journal-title":"J Hepatol"},{"key":"1733_CR19","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","volume":"65","author":"MCM Cheung","year":"2016","unstructured":"Cheung MCM, Walker AJ, Hudson BE, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;65:741\u20137.","journal-title":"J Hepatol"},{"key":"1733_CR20","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s12072-018-9914-6","volume":"13","author":"I Gentile","year":"2019","unstructured":"Gentile I, Scotto R, Coppola C, et al. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort). Hepatol Int. 2019;13:66\u201374.","journal-title":"Hepatol Int"},{"issue":"2111\u20132121","key":"1733_CR21","first-page":"e2118","volume":"154","author":"O El-Sherif","year":"2018","unstructured":"El-Sherif O, Jiang ZG, Tapper EB, et al. Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection. Gastroenterology. 2018;154(2111\u20132121):e2118.","journal-title":"Gastroenterology"},{"key":"1733_CR22","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1002\/hep.29097","volume":"65","author":"C Fernandez Carrillo","year":"2017","unstructured":"Fernandez Carrillo C, Lens S, Llop E, et al. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: analysis of data from the Hepa-C registry. Hepatology. 2017;65:1810\u201322.","journal-title":"Hepatology"},{"key":"1733_CR23","doi-asserted-by":"crossref","unstructured":"Asahina Y, Drafting Committee for Hepatitis Management Guidelines tJSoH. JSH Guidelines for the Management of Hepatitis C Virus Infection, 2019 Update; Protective Effect of Antiviral Therapy against Hepatocarcinogenesis. Hepatol Res 2020.","DOI":"10.1111\/hepr.13501"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-020-01733-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-020-01733-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-020-01733-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T01:14:03Z","timestamp":1633050843000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-020-01733-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["1733"],"URL":"https:\/\/doi.org\/10.1007\/s00535-020-01733-4","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,1]]},"assertion":[{"value":"27 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Satoshi Mochida received grants from Kowa Co, Ltd. CMIC Co., Ltd, AbbVie GK, Janssen Pharmaceutical K. K., EA Pharma Co, Ltd MIC Medical Corp. Sumitomo Dainippon Pharma Co., Ltd, Mochida Pharmaceutical Co., Ltd. Daiichi Sankyo Co., Ltd, Toray Indutries Inc, Chugai Pharmaceutical Co., Ltd, Asuka Pharmaceutical Co., Ltd, Eisai Co., Ltd. and Gilead Sciences, Inc. and is on the speakers\u2019 bureau for Gilead Sciences, Inc., Bristol-Myers Squibb Company, MSD, Otuka Pharmaceutical Co., Ltd. Sumitomo Dainippon Pharma Co., Ltd. Asuka Pharmaceutical Co., Ltd and AbbVie GK and received patent royalties from SRL Inc. Norifumi Kawada received grants from Gilead Sciences, Inc. and AbbVie GK. and is on the speakers\u2019 bureau for Gilead Sciences, Inc., MSD and AbbVie GK.. Nobuyuki Enomoto received grants from Gilead Sciences, Inc. and is on the speakers\u2019 bureau for Gilead Sciences, Inc.. Akio Ido received grants from AbbVie GK. and is on the speakers\u2019 bureau for Gilead Sciences, Inc., Bristol-Myers Squibb Company and AbbVie GK.. Masayuki Kurosaki is on the speakers\u2019 bureau for Gilead Sciences, Inc. Hiroshi Yatsuhashi received grants from AbbVie GK. Yoshiyuki Ueno received grants from EA Pharma Co and AbbVie GK. and is on the speakers\u2019 bureau for AbbVie GK., EA Pharma Co, and Otsuka Pharmaceutical Co. Yoshito Itoh received grants from AbbVie GK, Bristol-Myers Squibb Company, Gilead Sciences, Inc and MSD and is on the speakers\u2019 bureau for Gilead Sciences, Inc., Bristol-Myers Squibb Company, MSD and AbbVie GK.. Tatsuya Kanto is on the speakers\u2019 bureau for Gilead Sciences, Inc.and MSD. Goki Suda received grants from Gilead Sciences, Inc.. Naoya Kato received grants from Gilead Sciences, Inc., Bristol-Myers Squibb Company and AbbVie GK. and is on the speakers\u2019 bureau for Gilead Sciences, Inc., MSD, Bristol-Myers Squibb Company and AbbVie GK.. Yasuhiro Asahina belongs to a donation-funded department funded by Toray Industries Inc, Gilead Sciences Inc, AbbVie GK, and Fujirebio Inc, Chugai Pharmaceutical Co. Ltd. and MSD. Shuji Terai received grants from Intersterm Routo, Asuka, Tsumura, Chiome Biosciense, Systemx, Touso, Abbvie, Takeda, Eisai, Kyowa, BioMimetics Sympathies and Daiichisannkyo and is on the speakers\u2019 bureau for Gilead Sciences, Inc., Asuka, MSD, Otsuka, Daiichisannkyo and Takeda. Norio Akuta is on the speakers\u2019 bureau for Gilead Sciences, Inc., Bristol-Myers Squibb Company, MSD, Dainippon Sumitomo Pharma, Mitsubishi Tanabe Pharma Co. Ltd and AbbVie GK. Takahiro Kodama received grants from Gilead Sciences, Inc. and AbbVie GK.. Tetsuo Takehara received grants from Gilead Sciences, Inc., MSD, and AbbVie GK. and is on the speakers\u2019 bureau for Gilead Sciences, Inc., MSD, and AbbVie GK.. All other authors declare that they have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"University Hospital Medical Information Network (UMIN: 000036150).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"The trial registration number"}}]}}